Key points are not available for this paper at this time.
INTRODUCTION In a report that was published as a supplement to the November 1970 issue ofDiabetes, the University Group Diabetes Program (UGDP) concluded that in patients with adult-onset diabetes, "tolbutamide and diet may be less effective in prolonging life than diet alone... at least insofar as cardiovascular mortality is concerned."1,2Of the subjects treated with tolbutamide, 12.7% died from cardiovascular causes, as compared with 6.2% or fewer in the other treatment groups. As a result of these findings, the Food and Drug Administration (FDA) recommended that tolbutamide should be used only in patients who had adult-onset, stable diabetes that could not be controlled by diet alone, and who, for some good reason, could not be treated with insulin. The findings of the UGDP and the action of the FDA had a dramatic impact. Tolbutamide had been in general use in the treatment of diabetes since about 1956
A Mon, study studied this question.